Quest Diagnostics INC Form 4 insider transactions

Quest Diagnostics SVP & General Counsel Michael E. Prevoznik exercised stock options and sold a portion of the acquired common stock under a Rule 10b5-1 plan.

A Quest Diagnostics SVP and General Counsel exercised and sold common stock totaling 28,463 shares under a pre-established Rule 10b5-1 plan.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, sold 1,975 shares of common stock for $185 per share as part of a pre-arranged 10b5-1 sales plan.

Quest Diagnostics SVP Patrick Plewman exercised stock options and sold 4,532 shares of common stock under a pre-arranged Rule 10b5-1 plan.

Quest Diagnostics' SVP of Diagnostic Services, Patrick Plewman, plans to sell 1,975 shares of common stock on August 15, 2025, under a Rule 10b5-1 plan.

A senior executive at Quest Diagnostics sold a portion of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Quest Diagnostics SVP Patrick Plewman exercised stock options and sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

A senior executive at Quest Diagnostics completed pre-arranged stock option exercises and subsequent sales of common stock under a Rule 10b5-1 plan.

Quest Diagnostics Executive Vice President and CFO Sam Samad acquired 72 shares of common stock through a dividend reinvestment plan, increasing his direct beneficial ownership to 25,673 shares.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, acquired 80 shares of common stock through a dividend reinvestment plan.

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, reported the acquisition of 27 shares of common stock, signaling continued confidence in the company.

Quest Diagnostics director Wright L. Lassiter III reported the future acquisition of 7 shares of common stock through a dividend reinvestment plan under a Rule 10b5-1 trading plan.

A director at Quest Diagnostics Inc. has reported the acquisition of 79 shares of common stock through a dividend reinvestment plan, with the transaction dated for July 21, 2025, and filed early.

Mark E. Delaney, SVP & Chief Commercial Officer at Quest Diagnostics, reported the acquisition of 17 shares of common stock through a dividend reinvestment plan.

Robert B. Carter, a Director at Quest Diagnostics Inc., acquired 7 shares of common stock through a dividend reinvestment plan, increasing his beneficial ownership.

Quest Diagnostics Executive Vice President and CFO Sam Samad disposed of 850 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Quest Diagnostics Director Timothy M. Ring acquired 236 phantom stock units through elective deferrals of cash compensation, increasing his total holdings to 16,725.378 units.

Wright L. Lassiter, III, a Director at Quest Diagnostics Inc., acquired 160 phantom stock units through an elective deferral of cash compensation, increasing his total beneficial ownership to 520.854 units.

Director Robert B. Carter reports acquisition of 1,203 shares of common stock and disposal of 2,685 shares.

A Form 4 filing reveals that Quest Diagnostics Director Luis Diaz acquired and disposed of shares of common stock and was awarded restricted stock units.

Director Vicky B. Gregg reports changes in beneficial ownership of Quest Diagnostics Inc. common stock, including acquisition of 1,203 shares and disposal of an unspecified amount.

Tracey Doi, a director at Quest Diagnostics, reported the acquisition of 1,203 restricted stock units on May 15, 2025.

Director Timothy L. Main reports acquiring 1,203 shares of Quest Diagnostics common stock and disposing of an unspecified amount on May 15, 2025.

Director Denise M. Morrison reports acquisition of 1,203 restricted stock units in Quest Diagnostics.

Director Lassiter Wright III reports acquisition of 1,203 shares of Quest Diagnostics common stock through a restricted stock unit award and disposal of 9,037 shares on May 15, 2025.

Director Timothy Ring acquired 1,203 restricted stock units in Quest Diagnostics on May 15, 2025.

Director Gary M. Pfeiffer acquired 1,203 shares of Quest Diagnostics common stock on May 15, 2025, through an award of restricted stock units.

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, sold a total of 1,748 shares of common stock on May 12 and 13, 2025, under a pre-arranged Rule 10b5-1 sales plan.

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports acquiring 74 shares of common stock through a dividend reinvestment plan at a price of $164.422 per share.

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, reports the acquisition of common stock through dividend reinvestment and holdings in a 401(k) plan.